Download presentation
Presentation is loading. Please wait.
Published byIngvar Jensen Modified over 5 years ago
1
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg, MD, PhD, Odd Terje Brustugun, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 12, Pages (December 2012) DOI: /JTO.0b013e318275b346 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
2
FIGURE 1 Absolute (upper panel) and age-adjusted (lower panel) increase of mesothelioma incidence in Norway for men (blue line) and women (red line) from 1970 to 2009. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b346) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
3
FIGURE 2 The antimetabolite pemetrexed was not used in Norway before 2003; the first patient was treated in February 2003, and during the first 2 years 65 patients received this treatment. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b346) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
4
FIGURE 3 Survival for 1 year and 3 years for women (upper panel) and men (lower panel) over the last 40 years. OS, overall survival. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b346) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
5
FIGURE 4 Median survival for men diagnosed with malignant mesothelioma from 1970 to Ninety-five percent confidence intervals are shown. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b346) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.